Nektar Therapeutics (NASDAQ:NKTR) saw a downside of -4.41% to close Tuesday at $0.68 after subtracting -$0.03 on the day. The 5-day average trading volume is 3,688,580 shares of the company’s common stock. It has gained $0.8400 in the past week and touched a new high 1 time within the past 5 days. An average of 14,934,400 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 8,473,112.
NKTR’s 1-month performance is 29.46% or $0.1230 on its low of $0.5051 reached on 07/26/23. The company’s shares have touched a 52-week low of $0.51 and high of $4.79, with the stock’s rally to the 52-week high happening on 02/07/23. YTD, NKTR has lost -69.92% or -$1.5801 and has reached a new high 15 times. However, the current price is down -85.81% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NKTR stock investors last saw insider trading activity on Aug 16.ROBIN HOWARD W (President & CEO) most recently sold 19,998 shares at $0.78 per share on Aug 16. This transaction cost the insider $15,598. Chief R&D Officer, Zalevsky Jonathan, sold 9,703 shares at a price of $0.78 on Aug 16. Then, on Aug 16, Chief Legal Officer Wilson Mark Andrew sold 7,221 shares at a price of $0.78 per share. This transaction amounted to $5,632.
Valuation Metrics
NKTR stock has a beta of 0.91. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.45 while the price-to-book (PB) in the most recent quarter is 0.65.
Nektar Therapeutics’s quick ratio for the period ended June 29 was 8.30, with the current ratio over the same period at 8.70.. In terms of profitability, the gross margin trailing 12 months is 71.20%. The trailing 12-month EBITDA margin is -247.72%. The firm’s gross profit as reported stood at $70.42 million against revenue of $92.06 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -211.17% to -$51.12 million, while revenue of -$137.02 million was -168.04% off the previous quarter. Analysts expected NKTR to announce -$0.28 per share in earnings in its latest quarter, but it posted -$0.27, representing a 3.60% surprise. EBITDA for the quarter stood at more than -$53.45 million. NKTR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 297.32 million, with total debt at $124.75 million. Shareholders hold equity totaling $190.12 million.
Let’s look briefly at Nektar Therapeutics (NKTR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 43.41% to suggest the stock is trending Neutral, with historical volatility in this time period at 115.75%.
The stock’s 5-day moving average is $0.7219, reflecting a -15.99% or -$0.1294 change from its current price. NKTR is currently trading +31.71% above its 20-day SMA, -6.38% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +16.22% and SMA200 by-81.32%.
Stochastic %K and %D was 32.50% and 35.14% and the average true range (ATR) pointed at 0.0994. The RSI (14) points at 47.89%, while the 14-day stochastic is at 27.62% with the period’s ATR at 0.0915. The stock’s 9-day MACD Oscillator is pointing at -0.0958 and -0.0933 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Nektar Therapeutics (NASDAQ: NKTR), Jefferies upgraded it to a Hold rating. They previously had an Underperform rating on the stock. Analysts offering their rating for NKTR stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate NKTR as a “sell,”, while 6 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is NKTR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $0.60 and a high of $6.00, with their median price target at $1.75. Looking at these predictions, the average price target given by analysts is for Nektar Therapeutics (NKTR) stock is $2.35.
